/PRNewswire/ --Decision Resources Group finds that Biogen Idec's Tecfidera, the third-to-market oral disease-modifying therapy (DMT), has become the patient share leader among the oral options available for the treatment of relapsing forms of ... ADVFN India, 4 weeks ago
Biogen Idec''s Tecfidera Captures the Largest U.S. Neurologist-Reported Patient Share Among Oral Disease-Modifying Multiple Sclerosis Therapies Ten Months Post-Launch - Asian Hospital & Healthcare Management, 4 weeks ago
1 images for "Tecfidera Treated Patients"
Health Canada Approves New Strength For TECFIDERA(TM), A First-Line Oral Treatment For Multiple Sclerosis
TECFIDERA now available as 240 mg delayed-release capsules MISSISSAUGA, ON, Feb. 18, 2014 /CNW/ - Today, Biogen Idec Canada announces the Health Canada approval of TECFIDERA (dimethyl fumarate) 240 mg strength capsule, a first-line oral treatment ...Canada NewsWire, 1 month ago
NICE have said theyre minded to say no to allowing the new oral MS drug dimethyl fumarate (Tecfidera) to be freely available on the NHS in England and Wales for people with relapsing remitting MS . The drug was licensed earlier this month to ...Multiple Sclerosis Society, 1 month ago Dimethyl fumarate (BG-12, Tecfidera) - NICE gives initial "no" decision Multiple Sclerosis Trust, 1 month ago NICE says initial 'no' to MS drug BootsWebMD, 1 month ago
- Two-Year Data from Pivotal Phase 3 ADVANCE Study for PLEGRIDY (Peginterferon Beta-1a) to Be Presented - - New TECFIDERA® (dimethyl fumarate) Data Underscore Efficacy, Consistent with Growing Global Experience with Greater than 65,000 Patients ...Benzinga.com, 3 days ago Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting BusinessWeek, 3 days ago Company Update: Biogen Idec Inc (NASDAQ:BIIB) U.S. FDA approves Biogen's hemophilia B drug Alprolix Jutia Group, 2 weeks ago BIOGEN IDEC : to Report Clinical Data from Its Neurology Portfolio at AAN Annual Meeting 4 Traders, 1 day ago
Biogen Idec ( BIIB ), on the IBD 50 list of top-rated growth stocks, is working on a new oral drug for treating multiple sclerosis that has the potential for driving the biotech firm's next generation of MS therapies, according to a research note ...Investor's Business Daily, 1 week ago
Times are changing for Biogen Idec ( NASDAQ: BIIB ) . The longtime leader in the development of drugs for treating multiple sclerosis just expanded its territory. Last Friday, the Food and Drug Administration granted approval for Biogen's ...Motley Fool, 2 weeks ago
Summary Tcelna has the opportunity to provide patients with a first in line therapy for Secondary Progressive Multiple Sclerosis that is not toxic. Opexa investors that remain long term have the ability to reap huge rewards if the phase 2b trial ...Seeking Alpha, 1 month ago
Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 0, Authorised
This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...European Medicines Agency, 1 month ago
Tecfidera is approved by Scottish Medicines Consortium for Scots with relapsing-remitting multiple sclerosis
TECFIDERA is said to significantly reduce the number of MS relapses and slow the progression of the disease. A NEW oral drug for people with relapsing-remitting multiple sclerosis is to be made available in Scotland. Tecfidera (dimethyl ...Daily Record, 1 week ago
The cholesterol-lowering drugs known as statins are controversial for a number of reasons, but for people who are suffering with secondary progressive multiple sclerosis (MS), they may prove to be beneficial. A British team of researchers from ...EMax Health, 3 weeks ago
on your WebpageAdd Widget >Get your members hooked!